BDTX · CIK 0001701541 · operating
Black Diamond Therapeutics is a clinical-stage oncology company focused on discovering and developing targeted therapies for patients with genetically defined tumors. The company's pipeline centers on its MasterKey platform, which targets specific oncogenic mutations across multiple cancer types. The lead candidate, BDTX-1535, is a brain-penetrant EGFR inhibitor currently in Phase 2 testing for EGFR-mutant non-small cell lung cancer and Phase 1 evaluation for glioblastoma. The company is also advancing BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors in Phase 1 trials, and BDTX-4876, a selective FGFR2/3 inhibitor in preclinical development.
As a pre-revenue clinical-stage company, Black Diamond has no established revenue streams. The organization operates with a lean structure of 24 full-time employees and is based in Cambridge, Massachusetts. The company was formerly known as ASET Therapeutics before rebranding to Black Diamond Therapeutics in January 2018. Trading on Nasdaq, it operates within the broader biotechnology sector focused on oncology drug development.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-1.27 | $-1.27 | +32.4% | |
| 2023 | $-1.88 | $-1.88 | +25.4% | |
| 2022 | $-2.52 | $-2.52 | +27.4% | |
| 2021 | $-3.47 | $-3.47 | — | |
| 2020 | — | — | — | |
| 2019 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2024-12-31 | 2025-03-06 | 0001701541-25-000016 | SEC ↗ |
| 2023-12-31 | 2024-03-12 | 0001701541-24-000011 | SEC ↗ |
| 2022-12-31 | 2023-03-09 | 0001701541-23-000020 | SEC ↗ |
| 2021-12-31 | 2022-03-17 | 0001701541-22-000007 | SEC ↗ |
| 2020-12-31 | 2021-03-25 | 0001701541-21-000018 | SEC ↗ |
| 2019-12-31 | 2020-03-24 | 0001701541-20-000009 | SEC ↗ |